Related Experiment Videos
Plasma propranolol before, during, and after cardiopulmonary bypass
Clinical Pharmacology and Therapeutics
|December 1, 1981
Summary
Propranolol plasma levels decreased during cardiopulmonary bypass (CPB) but unexpectedly rose afterward. This sustained increase in propranolol levels post-CPB suggests redistribution and reduced hepatic elimination.
Area of Science:
- Pharmacokinetics
- Cardiovascular Surgery
- Anesthesiology
Background:
- Propranolol is a beta-blocker commonly used in patients with cardiovascular conditions.
- Understanding propranolol's behavior during cardiopulmonary bypass (CPB) is crucial for managing patients undergoing cardiac surgery.
Purpose of the Study:
- To evaluate changes in plasma propranolol levels before, during, and after cardiopulmonary bypass (CPB).
- To investigate the pharmacokinetic profile of propranolol in patients undergoing CPB.
Main Methods:
- Two groups of patients on long-term propranolol therapy were studied.
- Group 1 received intravenous propranolol before CPB; Group II received a placebo.
- Plasma propranolol levels were measured at multiple time points: pre-CPB, during CPB, and up to 240 minutes post-CPB.
Main Results:
- Plasma propranolol levels decreased by approximately 50% at the onset of CPB.
- Propranolol levels remained relatively stable during CPB.
- A significant and sustained increase in plasma propranolol levels was observed in all patients after CPB, exceeding levels during CPB.
Conclusions:
- Cardiopulmonary bypass significantly alters propranolol pharmacokinetics.
- The sustained rise in propranolol levels post-CPB may be attributed to redistribution from the lungs and reduced hepatic elimination.
- Further research is needed to elucidate the exact mechanisms behind this post-CPB propranolol level elevation.